Allogene Therapeutics Stock Performance
| ALLO Stock | USD 2.16 0.01 0.47% |
Allogene Therapeutics holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.65, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Allogene Therapeutics will likely underperform. Use Allogene Therapeutics downside variance, and the relationship between the sortino ratio and accumulation distribution , to analyze future returns on Allogene Therapeutics.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Allogene Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Allogene Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Acquisition by Humer Franz B of 61475 shares of Allogene Therapeutics subject to Rule 16b-3 | 12/04/2025 |
2 | Disposition of 47700 shares by Joshua Kazam of Allogene Therapeutics subject to Rule 16b-3 | 12/18/2025 |
3 | Why Allogene Therapeutics Inc. stock is seen as undervalued - Market Activity Recap Verified Stock Trade Ideas - | 12/19/2025 |
4 | UBS Initiates Coverage on Allogene Therapeutics with Buy Rating ALLO Stock News - GuruFocus | 01/07/2026 |
5 | Are Medical Stocks Lagging Allogene Therapeutics This Year | 01/09/2026 |
6 | 12 Health Care Stocks Moving In Tuesdays Pre-Market Session - Benzinga | 01/13/2026 |
7 | Disposition of 26269 shares by Roberts Zachary of Allogene Therapeutics at 1.56 subject to Rule 16b-3 | 01/21/2026 |
8 | Allogene Therapeutics EVP Zachary Roberts Sells 26,269 Shares | 01/23/2026 |
9 | Acquisition by Belldegrun Arie of 263033 shares of Allogene Therapeutics subject to Rule 16b-3 | 02/02/2026 |
10 | Allogene Therapeutics CEO David Chang Sells 95,269 Shares | 02/04/2026 |
11 | Earl Martin Douglas Sells 22,900 Shares of Allogene Therapeutics Stock | 02/06/2026 |
| Begin Period Cash Flow | 93.4 M | |
| Total Cashflows From Investing Activities | 75.7 M |
Allogene Therapeutics Relative Risk vs. Return Landscape
If you would invest 126.00 in Allogene Therapeutics on November 19, 2025 and sell it today you would earn a total of 89.50 from holding Allogene Therapeutics or generate 71.03% return on investment over 90 days. Allogene Therapeutics is currently generating 1.0563% in daily expected returns and assumes 6.0301% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Allogene, and 79% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Allogene Therapeutics Target Price Odds to finish over Current Price
The tendency of Allogene Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.16 | 90 days | 2.16 | near 1 |
Based on a normal probability distribution, the odds of Allogene Therapeutics to move above the current price in 90 days from now is near 1 (This Allogene Therapeutics probability density function shows the probability of Allogene Stock to fall within a particular range of prices over 90 days) .
Allogene Therapeutics Price Density |
| Price |
Predictive Modules for Allogene Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Allogene Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Allogene Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Allogene Therapeutics is not an exception. The market had few large corrections towards the Allogene Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Allogene Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Allogene Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.68 | |
β | Beta against Dow Jones | 1.65 | |
σ | Overall volatility | 0.17 | |
Ir | Information ratio | 0.13 |
Allogene Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Allogene Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Allogene Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Allogene Therapeutics is way too risky over 90 days horizon | |
| Allogene Therapeutics appears to be risky and price may revert if volatility continues | |
| Allogene Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 22 K. Net Loss for the year was (257.59 M) with loss before overhead, payroll, taxes, and interest of (166.49 M). | |
| Allogene Therapeutics currently holds about 490.49 M in cash with (200.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Allogene Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Earl Martin Douglas Sells 22,900 Shares of Allogene Therapeutics Stock |
Allogene Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Allogene Stock often depends not only on the future outlook of the current and potential Allogene Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Allogene Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 194.8 M | |
| Cash And Short Term Investments | 292.5 M |
Allogene Therapeutics Fundamentals Growth
Allogene Stock prices reflect investors' perceptions of the future prospects and financial health of Allogene Therapeutics, and Allogene Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Allogene Stock performance.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 229.45 M | ||||
| Shares Outstanding | 224.73 M | ||||
| Price To Earning | (3.30) X | ||||
| Price To Book | 1.28 X | ||||
| Price To Sales | 11,631 X | ||||
| Revenue | 22 K | ||||
| Gross Profit | (166.49 M) | ||||
| EBITDA | (243.33 M) | ||||
| Net Income | (257.59 M) | ||||
| Cash And Equivalents | 490.49 M | ||||
| Cash Per Share | 3.41 X | ||||
| Total Debt | 90.76 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 11.42 X | ||||
| Book Value Per Share | 1.41 X | ||||
| Cash Flow From Operations | (200.3 M) | ||||
| Earnings Per Share | (0.98) X | ||||
| Market Capitalization | 404.51 M | ||||
| Total Asset | 548.71 M | ||||
| Retained Earnings | (1.82 B) | ||||
| Working Capital | 267.86 M | ||||
| Current Asset | 418.72 M | ||||
| Current Liabilities | 26.36 M | ||||
About Allogene Therapeutics Performance
By examining Allogene Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Allogene Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Allogene Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.54) | (0.57) | |
| Return On Capital Employed | (0.61) | (0.64) | |
| Return On Assets | (0.54) | (0.57) | |
| Return On Equity | (0.70) | (0.74) |
Things to note about Allogene Therapeutics performance evaluation
Checking the ongoing alerts about Allogene Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Allogene Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Allogene Therapeutics is way too risky over 90 days horizon | |
| Allogene Therapeutics appears to be risky and price may revert if volatility continues | |
| Allogene Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 22 K. Net Loss for the year was (257.59 M) with loss before overhead, payroll, taxes, and interest of (166.49 M). | |
| Allogene Therapeutics currently holds about 490.49 M in cash with (200.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Allogene Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Earl Martin Douglas Sells 22,900 Shares of Allogene Therapeutics Stock |
- Analyzing Allogene Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Allogene Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Allogene Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Allogene Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Allogene Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Allogene Therapeutics' stock. These opinions can provide insight into Allogene Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Will Biotechnology sector continue expanding? Could Allogene diversify its offerings? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Allogene Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Allogene Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Allogene Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Allogene Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.